EDIT - エディタス・メディシン (Editas Medicine Inc.) エディタス・メディシン

 EDITのチャート


 EDITの企業情報

symbol EDIT
会社名 Editas Medicine Inc (エディタス・メディシン)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 エディタス・メディシン(Editas Medicine Inc.)はゲノム編集会社である。同社は、疾患の原因となる遺伝子を編集することによって、遺伝子疾患を有する患者を治療する。同社はゲノム編集技術分野での開発と商品化を通じて事業を展開する。同社はクラスター化され、規則的に間隔を置いて配置された短いパリンドローム反復(CRISPR)技術に基づくゲノム編集プラットフォームを開発している。CRISPRは、CRISPR関連タンパク質9(Cas9)またはPrevotellaおよびFrancisella 1(Cpf1)由来のCRISPRのいずれかを含む酵素からなるタンパク質 - リボ核酸(RNA)複合体を使用し、特定のデオキシリボ核酸(DNA)配列を認識するように設計されたガイドRNA分子に結合する。同社のプラットフォームは、ヌクレアーゼエンジニアリング、デリバリー、コントロールと特異性、指示編集の4つのコンポーネントから構成される。同社のプログラムには、眼疾患、免疫腫瘍学のための人工T細胞療法、および追加の研究プログラムが含まれる。同社はLeber先天性アメロシスタイプ10(LCA10)のゲノム編集治療薬を開発している。   エディタス・メディシンは米国のライフサイエンス企業。病原性遺伝子ゲノム編集により、遺伝子関連疾患を治療する。ゲノム編集プラットフォ―ム「CRISPR/Cas9」を商標登録し、特定のDNAを認識し削除した後ゲノム配列を編集する技術を開発。同社プラットフォ―ムにはヌクレア―ゼ、送達システム、ゲノム編集などを含む。本社はマサチュ―セッツ州ケンブリッジ。  As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a (also known as Cpf1) genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. For the latest information and scientific presentations, please visit www.editasmedicine.com.
本社所在地 11 Hurley Street Cambridge MA 02141 USA
代表者氏名 James C. Mullen ジェームスC.ミューレン
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 617-401-9000
設立年月日 41518
市場名 NASDAQ National Market System
ipoyear 2016年
従業員数 112人
url www.editasmedicine.com
nasdaq_url https://www.nasdaq.com/symbol/edit
adr_tso
EBITDA EBITDA(百万ドル) -131.47100
終値(lastsale) 27.88
時価総額(marketcap) 1329196954.72
時価総額 時価総額(百万ドル) 1323.476
売上高 売上高(百万ドル) 21.24800
企業価値(EV) 企業価値(EV)(百万ドル) 112.34
当期純利益 当期純利益(百万ドル) -132.45000
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Editas Medicine Inc revenues increased from $3.8M to $11.3M. Net loss increased 21% to $69.7M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development - Balancing increase of 56% to $46.1M (expense) General and administrative - Balancing increase of 14% to $22.9M (expense).

 EDITのテクニカル分析


 EDITのニュース

   Editas Medicine Stock: Q3 Update; 2 Clinical Catalysts To Watch (NASDAQ:EDIT)  2022/11/04 11:45:18 Seeking Alpha
I believe EDIT will be unlikely to catch up with peers with much more advanced clinical studies. See here for upcoming catalysts and key risks facing EDIT.
   Editas Medicine Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag  2022/11/04 10:14:17 Simply Wall St
Editas Medicine ( NASDAQ:EDIT ) Third Quarter 2022 Results Key Financial Results Revenue: US$42.0k (down 99% from 3Q…
   Editas Medicine rises 7% on Q3 earnings beat (NASDAQ:EDIT)  2022/11/02 15:43:01 Seeking Alpha
Editas Medicine (EDIT) is trading 7% higher after the company posted better-than expected Q3 GAAP EPS. The company recorded collaboration and other research and development revenues…
   Editas Medicine, Inc. (EDIT) Q3 2022 Earnings Call Transcript  2022/11/02 14:50:29 Seeking Alpha
Editas Medicine, Inc. (NASDAQ:NASDAQ:EDIT) Q3 2022 Earnings Conference Call November 02, 2022 08:00 AM ET Company Participants Ron Moldaver - Investor Relations Gilmore O’Neill - Chief…
   A turnaround for Editas Medicine, a CRISPR laggard, hinges on updates on key treatments  2022/11/02 14:42:54 STAT News
Other CRISPR companies command multibillion-dollar valuations, but Editas trades below its IPO price following upheaval and clinical delay.
   Editas Medicine, Inc. (EDIT) Management Presents at Morgan Stanley 20th Annual Global Healthcare Conference Call Transcript  2022/09/12 18:53:03 Seeking Alpha
Editas Medicine, Inc. (NASDAQ:NASDAQ:EDIT) Morgan Stanley 20th Annual Global Healthcare Conference Call September 12, 2022, 10:30 AM ET Company Participants Gilmore O’Neill - President and…
   Editas Medicine, Inc. (EDIT) Presents at 2022 Wells Fargo Healthcare Conference (Transcript)  2022/09/07 21:57:06 Seeking Alpha
Editas Medicine, Inc. (NASDAQ:NASDAQ:EDIT) 2022 Wells Fargo Healthcare Conference September 07, 2022 01:55 PM ET Company Participants Gilmore O''Neill - Chief Executive Officer Mark Shearman…
   Have you been able to find a good deal on Editas Medicine Inc.’s shares?  2022/09/07 11:24:00 US Post News
Editas Medicine Inc. (NASDAQ:EDIT) marked $14.30 per share on Tuesday, down from a previous closing price of $14.83. While Editas Medicine Inc. has underperformed by -3.57%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, EDIT fell by -79.05%, with highs and lows ranging from $72.50 to […]
   Editas Medicine Inc. (NASDAQ:EDIT) Could Actually Go To $80.00 In 12 Months  2022/09/02 14:00:00 Marketing Sentinel
In last trading session, Editas Medicine Inc. (NASDAQ:EDIT) saw 1.31 million shares changing hands with its beta currently measuring 2.04. Company’s recent per share price level of $15.42 trading at $0.72 or 4.90% at ring of the bell on the day assigns it a market valuation of $1.16B. That closing price of EDIT’s stock is … Editas Medicine Inc. (NASDAQ:EDIT) Could Actually Go To $80.00 In 12 Months Read More »
   Editas Medicine: Management Upbeat After Lifting Of Clinical Hold  2022/08/25 13:24:32 Seeking Alpha
Editas Medicine''s engraftment trial experiment made positive headway in Q2 2022. Click here to see EDIT''s growth prospects and potential risks.
   Why Editas Medicine Stock Is Jumping Today | The Motley Fool  2021/06/28 16:17:15 The Motley Fool
Good news for Intellia was viewed as good news for Editas.
   Why Editas Medicine Stock Is Jumping 13.9% This Week  2021/06/25 10:01:00 The Motley Fool
The company received a go-ahead to enroll kids in a study of its lead gene-editing candidate.
   Enrollment underway in Editas Medicine''s pediatric cohort of EDIT-101 study in inherited retinal disorder  2021/06/23 11:38:36 Seeking Alpha
   Editas Medicine Reports Inducement Grants to New Chief Scientific Officer and Chief Regulatory Officer  2021/06/15 20:01:00 Intrado Digital Media
CAMBRIDGE, Mass., June 15, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced the grant of inducement awards to the Companys newly appointed Executive Vice President and Chief Scientific Officer, Mark Shearman, Ph.D., and Senior Vice President and Chief Regulatory Officer, Chi Li, Ph.D. In connection with the appointments, the Editas Medicine Board of Directors approved a stock option grant and a restricted stock unit award to each of Drs. Shearman and Li as inducements material to their entering into employment with Editas Medicine in accordance with Nasdaq Listing Rule 5635(c)(4). Drs. Shearmans and Lis stock options provide for the purchase of up to 52,718 shares and 44,202 shares, respectively, of Editas Medicine common stock at a price of $38.53 per share, the closing price per share of Editas Medicine common stock as reported by Nasdaq on the date of grant, and vest over four years, with 25 percent of the shares vesting on the first anniversary of each individuals employment start date, and the remainder vesting ratably at the end of each subsequent month thereafter, subject to their continued service relationship with Editas Medicine through the applicable vesting dates.
   Editas Medicine names new chief science and chief regulatory officers  2021/06/14 13:14:46 Seeking Alpha

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 エディタス・メディシン EDIT Editas Medicine Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)